This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Research == Biggar's research includes many different areas from different fields within molecular biology, biochemistry, and physical biochemistry. His main areas of research interest are Oxidative Cell Stress, Functional Proteomics, Bioinformatics, and Molecular Pharmacology. He is particularly known for his research in the new field of Non-histone Lysine Methylation and its relation to both functional proteomics and cell stress.
Muscimol is a potent GABAA receptor full agonist, activating the receptor for the brain's principal inhibitory neurotransmitter, γ-aminobutyric acid (GABA). Muscimol binds to the same site on the GABAA receptor complex as GABA itself, unlike other GABAergic drugs such as barbiturates, benzodiazepines, and Z-drugs, which interact with separate allosteric sites. GABAA receptors are widely distributed in the brain, so when muscimol is administered, it alters neuronal activity in multiple regions including the cerebral cortex, hippocampus, and cerebellum. By mimicking GABA, muscimol activates these receptors, leading to the opening of chloride channels and subsequent hyperpolarization of neurons. This results in decreased neuronal excitability, which is crucial for maintaining the balance between excitation and inhibition in the central nervous system. Muscimol was originally reported to show relatively uniform effects on GABAA receptors of differing subunit compositions. However, it was found to act as a superagonist of extrasynaptic α4β3δ subunit-containing GABAA receptors (EmaxTooltip maximal efficacy = 120 to 140% relative to GABA). This was found to be due to reduced receptor desensitization with muscimol compared to GABA. Subsequent research has found that muscimol is a preferential agonist of the relatively small population of extrasynaptic and/or δ subunit-containing GABAA receptors and that these receptors have a substantial contribution to its effects.
The Wall Street Journal reported that Russia and Iran plan to build a plant for making improved Shahed 136 drones in Yelabuga, Russia, and make there at least 6,000 drones for the war in Ukraine. Embargo and price ceilings on Russian oil products, introduced by EU, Australia and G7, came into effect. Russian shelling and rocket strikes damaged houses and civilian infrastructure in Kherson Oblast, Druzhkivka (Donetsk Oblast) and Kharkiv. In addition, the Kharkiv National Academy of Urban Economy was partially destroyed.
Sources: en.wikipedia.org
=== Scams === In the early 2000s, numerous companies advertised açaí products online, with many ads featuring counterfeit testimonials and products. In 2009, açaí scams were ranked No. 1 on the U.S. Federal Trade Commission's "scams and rip-offs" list, so that by 2011 sales of açaí flattened as the fad waned. According to the Washington, D.C.–based Center for Science in the Public Interest thousands of consumers had trouble stopping recurrent charges on their credit cards when they canceled free trials of some açai-based products. In 2003, American celebrity doctor Nicholas Perricone included açaí berries among "superfoods", but such extravagant marketing claims regarding açaí as miracle cures for everything from obesity to attention-deficit disorder were challenged in subsequent studies. The FTC handed down an $80 million judgement in January 2012 against five companies that were marketing açaí berry supplements with fraudulent claims that their products promoted weight loss and prevented colon cancer. One company, Central Coast Nutraceuticals, was ordered to pay a $1.5 million settlement.
Scientists at the Allen Institute reported that they identified specific cell types in the brains of mice that undergo changes with age and a specific area where many of the changes occur. Researchers at Korea University, Yonsei University, the University of California, Berkeley, and Tufts University found that the protein HMGB1 induces cellular senescence throughout the body and blocking it can inhibit senescence, reduce systemic inflammation, and improve muscle regeneration. An experiment at the Max Planck Institute for the Biology of Ageing in which mice were given Rapamycin and Trametinib found that lifespan and healthspan were significantly extended in both male and female mice. A study at the University of Haifa found that synchronization between organs declines with age except for the immune system, with inflammatory responses becoming more coordinated between different organs the older a person gets. The researchers mapped the biological systems and specific genes involved, suggesting that the discovery could improve diagnostics and with time pave the way to interventions into the process. Researchers at the University of California, San Francisco, reported that the protein FTL1 may be a major cause of brain aging, finding that blocking the protein in mice restored youthful brain function. A study led by Lige Leng of Xiamen University suggested that a drop in the brain protein MEN1 in the hypothalamus may be a driver of physiological aging, and that an amino acid supplement may counter some of the effects.
== Applications == Affibody molecules can be used for protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostic imaging and targeted therapy. The second generation of Affibody molecule, ABY-025, binds selectively to HER2 receptors with picomolar affinity. These Affibody molecules are in clinical development for tumor diagnosis. Anti-HER2 Affibody molecule, fused with albumin binding domain (ABD), denoted as ABY-027, labeled with Lutetium-177 provided reduction of renal and hepatic uptake of radioactivity in mice xenografts.. Further preclinical research evaluated an optimised version of the same ABD-fused Affibody, reporting an improved therapeutic effect in combination with trastuzumab. In October 2025, a refined variant of the ABD-fused Affibody molecule targeting HER2, radiolabelled with Lutetium-177, entered clinical trials to assess its safety, biodistribution and tolerability in patients with metastatic breast cancer. Recently, anti-ZEGFR Affibody ZEGFR:2377 labeled with technetium-99m was successfully used to visualize ZEGR expressing tumor in mice xenograft also.
=== Reliability === Shock resistance: LEDs, being solid-state components, are difficult to damage with external shock, unlike fluorescent and incandescent bulbs, which are fragile. Thermal runaway: Parallel strings of LEDs will not share current evenly due to the manufacturing tolerances in their forward voltage. Running two or more strings from a single current source may result in LED failure as the devices warm up. If forward voltage binning is not possible, a circuit is required to ensure even distribution of current between parallel strands. Slow failure: LEDs mainly fail by dimming over time, rather than the abrupt failure of incandescent bulbs. Lifetime: LEDs can have a relatively long useful life. One report estimates 35,000 to 50,000 hours of useful life for white LEDs, though time to complete failure may be shorter or longer. Fluorescent tubes typically are rated at about 10,000 to 25,000 hours, depending partly on the conditions of use, and incandescent light bulbs at 1,000 to 2,000 hours. Several DOE demonstrations have shown that reduced maintenance costs from this extended lifetime, rather than energy savings, is the primary factor in determining the payback period for an LED product. Cycling: LEDs are ideal for uses subject to frequent on-off cycling, unlike incandescent and fluorescent lamps that fail faster when cycled often, or high-intensity discharge lamps (HID lamps) that require a long time to warm up to full output and to cool down before they can be lighted again if they are being restarted.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.